Novel miR-5088-5p promotes malignancy of breast cancer by inhibiting DBC2

• Published in: Molecular therapy. Nucleic acids 2021-09, Vol.25, p.127-142
• Main Authors: Seok, Hyun Jeong, Choi, Young Eun, Choi, Jae Yeon, Yi, Joo Mi, Kim, Eun Joo, Choi, Mi Young, Lee, Su-Jae, Bae, In Hwa
• Format: Article
• Language: English
• Subjects: DBC2; Fyn; metastasis; methylation; miR-5088-5p; Original; tumorigenicity
• ISSN: 2162-2531; 2162-2531
• DOI: 10.1016/j.omtn.2021.05.004

Breast cancer is the most common female cancer in the world. Despite the active research on metastatic breast cancer, the treatment of breast cancer patients is still difficult because the mechanism is not well known. Therefore, research on new targets and mechanisms for diagnosis and treatment of breast cancer patients is required. On the other hand, microRNA (miRNA) has the advantage of simultaneously regulating the expression of many target genes, so it has been proposed as an effective biomarker for the treatment of various diseases including cancer. This study analyzed the role and mechanism of DBC2 (deleted in breast cancer 2), which is known to inhibit its expression in breast cancer, and proposed microRNA (miR)-5088-5p, which regulates its expression. It was revealed that the biogenesis of miR-5088-5p was upregulated by hypomethylation of its promoter, promoted by Fyn, and was involved in malignancy in breast cancer. With the use of the cellular level, clinical samples, and published data, we verified that the expression patterns of DBC2 and miR-5088-5p were negatively related, suggesting the potential as novel biomarkers for the diagnosis of breast cancer patients. [Display omitted] The effects of DBC2, which is downregulated in breast cancer, and miR-5088-5p, which regulates its expression, on malignancy of breast cancer were studied. It was confirmed that miR-5088-5p expression was increased by Fyn induced its hypomethylation. Therefore, DBC2 and miR-5088-5p have potential as new biomarkers for diagnosing breast cancer malignancy.